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Fatal Measles 
without Rash in 
Immunocompetent 
Adult, France
To the Editor: The reemergence 
of measles in Europe is a reminder 
of the forgotten risk for severe 
illness and death associated with this 
disease in industrialized countries. 
Since 2008, >20,000 measles cases 
and 9 measles-associated deaths 
(in 7 immunocompromised and 2 
immunocompetent persons) have 
been reported to the French Institute 
for Public Health. Among these cases, 
the reported causes of death were 
pneumonia and/or acute respiratory 
distress syndrome (ARDS) (n = 7) and 
encephalitis (n = 2). All patients except 
1, an immunocompromised patient, 
had the typical morbillous rash. We 
report another fatal case of measles, 
with intractable ARDS but no rash, 
in an apparently immunocompetent 
adult.
The patient was a 29-year-
old woman in Grenoble, France, 
who smoked but had no relevant 
medical history except an episode of 
depression. In 2011, she sought care 
for fever, cough, coryza, diarrhea, 
and a 10-kg weight loss over 10 days. 
A general practitioner empirically 
prescribed pristinamycin and oral 
prednisone (60 mg/d for 5 d) for 
sinusitis. Five days later, the patient 
was admitted to the hospital because 
of persistent signs and symptoms. 
Physical examination at admission 
(day 1) detected fever (38.5°C), 
dyspnea, and a low body mass index of 
17.5 kg/m2. Hematologic tests showed 
nonregenerative anemia (hemoglobin 
concentration 9 g/dL) and leukopenia 
(2.2 × 109 leukocytes/L) with profound 
lymphopenia (0.2 × 109 lymphocytes/L) 
and mild thrombocytopenia (135.0 × 
109 platelets/L). A chest radiograph 
showed bilateral diffuse interstitial 
infi ltrates. Antimicrobial therapy with 
levofl oxacin and ceftriaxone was 
started. 
On day 2, several examinations 
were conducted to explore 
the possibility of underlying 
immunosuppressive disease. Body 
scans showed no adenopathy or lesions 
suggestive of cancer. HIV test result 
was negative. General immunologic 
test results were within normal limits 
(immunoglobulin quantifi cation, 
autoantibody testing) or consistent 
only with an acute viral infection 
(serum protein electrophoresis). A 
bone marrow biopsy sample indicated 
isolated erythroblastopenia with no 
abnormality of other cell lineages 
(PCR for parvovirus B19 was 
negative). 
On day 3, because of severe 
respiratory failure, the patient was 
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transferred to the intensive care unit, 
where the diagnosis of ARDS was 
confi rmed and mechanical ventilation 
was started. Treatment with 
tazocillin/tazobactam, ciprofl oxacin, 
amphotericin B, and acyclovir was 
also started. Microbiological fi ndings 
from bronchoalveolar lavage (BAL) 
samples were repeatedly negative for 
bacteria, mycobacteria, fungi, and 
Pneumocystis jirovecii. Cytology 
of BAL samples showed an acute 
infl ammatory response with atypical 
epithelial cells, supporting a diagnosis 
of viral infection. However, none 
of 14 respiratory viruses or human 
herpesviruses type 1, 3, 4, 5, or 6 
were recovered from BAL samples by 
PCR. Blood and urine culture results 
were repeatedly negative, as were 
serologic test results for Legionella 
spp., Mycoplasma pneumoniae, and 
Chlamydia pneumoniae.
On day 5, because of refractory 
ARDS, venoarterial extracorporal 
membrane oxygenation was started. 
On day 6, the results of a broad 
serologic investigation demonstrated 
isolated IgM against measles virus. 
The patient was additionally given 
ribavirin, corticosteroids, and 
intravenous immunoglobulin. On day 
10, the lymphocyte level had returned 
to reference range and the anemia 
had become regenerative. However, 
the patient’s respiratory condition did 
not improve, and after 2 weeks of the 
oxygenation therapy, the patient died 
of hemorrhagic shock. Her parents 
declined an autopsy.
PCR testing of the patient’s saliva 
by the French National Reference 
Center confi rmed the presence of 
measles virus. Retrospective testing 
of serum, bone marrow, and BAL 
specimens collected during days 
2–20 of hospitalization demonstrated 
measles virus RNA. The strain was 
identifi ed as genotype D4, which is the 
epidemic strain circulating in France 
and elsewhere in Europe (1). The 
patient had no history of enanthem 
(Koplik spots) or morbilliform rash 
before or after symptom onset and 
no documented history of measles 
vaccination.
Deaths from measles with 
pneumonia or ARDS but without 
rash have been reported but mostly in 
patients with defi cient cell-mediated 
immunity (2–6). Despite all our 
testing, we found no indications of 
an underlying immunosuppressive 
disease in this patient; however, we 
cannot categorically rule out this 
possibility, especially that of a primary 
immunodefi ciency. The initial therapy 
with corticosteroids and the patient’s 
weight loss could also have interfered 
with her cellular immune response. 
The diagnosis of ARDS caused by 
measles was supported by detection of 
the measles genome in BAL samples 
and body fl uids in the absence of 
any other pathogen, but pulmonary 
superinfection with unidentifi ed 
pathogens could not be ruled out. 
Detection of the measles genome and 
isolated erythroblastopenia in the bone 
marrow biopsy sample is consistent 
with reports that measles virus can 
infect erythroid progenitors and 
interfere indirectly with hematopoiesis 
(7,8). Although ribavirin and passive 
immunotherapy have been reported to 
aid in recovery from severe measles 
pneumonia, their clinical effi cacy 
is still unproven (9,10); and for the 
patient reported here, they were 
probably used too late.
This unusual case underscores 
the need for physicians to consider 
the diagnosis of measles, even in 
the absence of classical clinical 
features, during measles outbreaks. 
It also reemphasizes the insuffi cient 
vaccination coverage against measles 
in France.
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To the Editor: Multidrug 
resistance in bacteria isolated from 
animals is an emerging phenomenon, 
mirroring what is happening among 
humans. During the past decade, 
expanded-spectrum β-lactamases in 
Enterobacteriaceae from humans 
(1) and animals (2) worldwide have 
been reported. Among humans, as a 
consequence of this high rate, use of 
carbepenems is increasing selection 
pressure; carbapenem-resistant gram-
negative organisms are increasingly 
reported, including carbapenemase-
producing Enterobacteriaceae and 
Acinetobacter spp. (3).
The most commonly acquired 
carbapenemases identifi ed in 
Acinetobacter spp. correspond to 
carbapenem-hydrolyzing class D 
β-lactamases (3). In particular, 
the worldwide spread of OXA-
23–producing A. baumannii is 
considered a serious threat; those 
strains are frequently involved in 
nosocomial outbreaks for which 
therapeutic options are extremely 
limited (3,4). Our study objective was 
to evaluate the possible occurrence 
of carbapenemase-producing gram-
negative bacteria in dairy cattle in 
France.
In August 2010, at a dairy farm 30 
km from Paris, France, rectal swabs 
were collected from 50 cows. Samples 
were precultured in buffered peptone 
water and incubated for 18 h at 37°C. 
Cultures were inoculated by streaking 
100 μL of the suspensions onto 
Drigalski agar plates (bioMérieux, 
Balmes-les-Grottes, France) con-
taining 1 μg/mL of imipenem to 
select for carbapenem-resistant gram-
negative isolates. Of the 50 samples, 
9 produced growth on imipenem-
containing plates. All colonies tested 
(10 colonies/sample) by using the 
API 20 NE (bioMérieux) system were 
fi rst identifi ed as A. lwoffi i. Molecular 
techniques based on sequencing of 
the gyrA, gyrB, and rpoB genes (5) 
enabled more precise identifi cation 
and indicated that all isolates belonged 
to the Acinetobacter genomospecies 
(DNA group) 15TU, which is known 
to be phylogenetically related to A. 
lwoffi i and which has been reportedly 
isolated from sewage, freshwater 
aquaculture habitats, trout intestines, 
and frozen shrimp (6).
One colony per sample was 
retained for further investigation 
(isolates BY1 to BY9). Susceptibility 
testing and MIC determinations were 
performed by disk-diffusion assay 
(Sanofi -Diagnostic Pasteur, Marnes-
la-Coquette, France) and Etest 
(AB bioMérieux, Solna, Sweden) 
(Table). All isolates except 1 were 
resistant to penicillins, combinations 
of penicillins and β-lactamase 
inhibitors, and carbapenems but 
susceptible to cefotaxime and of 
reduced susceptibility to ceftazidime. 
Isolate BY1 showed higher MICs 
for carbapenems (Table). In 
addition, all isolates were resistant 
to tetracycline, kanamycin, and 
fosfomycin and remained susceptible 
to fl uoroquinolones, chloramphenicol, 
gentamicin, amikacin, tobramycin, and 
sulfonamides. Susceptibility profi les 
of 3 Acinetobacter genomospecies 
15TU reference strains showed 
that they were fully susceptible to 
penicillins, carbapenems, tetracycline, 
and kanamycin.
Clonal diversity between the 
isolates was assessed by pulsed-
fi eld gel electrophoresis (5), which 
showed 6 distinct genotypes. Isolate 
BY1 corresponded to a single clone 
(data not shown), which indicated 
that the occurrence of Acinetobacter 
genomospecies 15TU strains among 
these animals was not the result of 
dissemination of a single clone.
PCR detection and sequencing 
of genes that encode carbapenem-
hydrolyzing class D β-lactamases 
(5) showed that the 9 Acinetobacter 
genomospecies 15TU isolates har-
bored a blaOXA-23 gene, whereas the 3 
reference strains remained negative. 
Sequencing confi rmed that all isolates 
expressed β-lactamase OXA-23, 
which is known to be widespread in 
A. baumannii.
Mating-out assays and plasmid 
electroporation assays were per-
formed by using blaOXA-23–positive 
Acinetobacter spp. isolates as donors 
and rifampin-resistant A. baumannii 
BM4547 isolates as a recipient strain 
(5); however, these assays were 
unsuccessful. Plasmid DNA analysis 
(5) gave uninterpretable results, with 
DNA degradations.
The genetic structures surrounding 
the blaOXA-23 gene were investigated by 
PCR mapping (7), which identifi ed 
transposon Tn2008 in isolate BY2 
only. Tn2008 is a major vehicle for 
the spread of the blaOXA-23 gene in A. 
baumannii in the People’s Republic 
of China (8) and the United States 
(9). In the other isolates, the ISAba1 
element of Tn2008 had been truncated 
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